Trial Profile
Phase II Study of Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Jun 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms NUPAT-01
- 01 Jun 2022 Results published in the Annals of Surgery
- 08 Sep 2020 Planned End Date changed from 1 Jun 2020 to 1 Jun 2023.
- 08 Sep 2020 Status changed from recruiting to active, no longer recruiting.